Malvern pharmaceutical company ordered to pay more than $1.5 billion after admitting it mislead doctors about a powerful opioid
The company has also paid $450 million into trusts funding state and local efforts to combat the opioid crisis, the spokesperson said, noting this covers the company’s criminal forfeiture payment. Federal officials said that while EHSI’s “corporate affiliates emerged from bankruptcy” last month, EHSI itself will “cease to operate in its current form and not emerge from bankruptcy.”concerns had been raised for years about oxymorphone, which is three times more powerful than morphine
Endo, which is headquartered in Ireland but operates from Malvern, later pulled the drug from the market.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: